Last reviewed · How we verify
NCT06140433: VSC
Vital Signs Camera Study
NA trial testing VSC-MEDlib in Respiration Rate in 94 participants. Completed in 15 March 2024.
15 March 2024
Quick facts
| Lead sponsor | Philips Clinical & Medical Affairs Global |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | screening |
| Enrollment | 94 |
| Start date | 2 February 2024 |
| Primary completion | 15 March 2024 |
| Estimated completion | 15 March 2024 |
| Sites | 1 location across Netherlands |
Drugs / interventions tested
- VSC-MEDlib
Conditions studied
- Respiration Rate — all drugs for Respiration Rate →
- Heart Rate — all drugs for Heart Rate →
Sponsor
Philips Clinical & Medical Affairs Global — full company profile →
Who can join
18 and older, any sex, with Respiration Rate or Heart Rate. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is a single center, prospective clinical investigation which is balanced for gender, age, Body Mass Index (BMI) and skin color. Simultaneous measurements of PR and RR on study participants will be collected in conditions described in IFU and various suboptimal conditions. The study participants will be recorded with the VSC demo app (together with a compatible camera and computing hardware) and reference devices. PR and RR data to be collected by the VSC demo app, will be post-processed after the clinical investigation and compared with the reference devices. Persons who are willing to participate will be asked to provide their consent. Primary objective: • To assess the clinical safety and effectiveness of Pulse Rate (PR) and Respiration Rate (RR) measured with the VSC-MEDlib within the intended use compared to the gold-standard reference devices. Exploratory objective: • To assess the clinical safety and effectiveness of Pulse Rate and Respiration Rate measured with the VSC-MEDlib during suboptimal circumstances (outside the scope of the intended use), compared to the gold-standard reference devices.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06140433
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Philips Clinical & Medical Affairs Global trials
Trials by the same sponsor.
- NCT07521735 — NEXT GEN - PHILIPS OPTIMUS · recruiting
- NCT07368036 — MR 7700 Multinuclear Application Clinical Trial · NA · not yet recruiting
- NCT07449715 — Respiration From Pleth Validation · recruiting
- NCT07317479 — Clinical Study for P-MAR · not yet recruiting
- NCT07317427 — Precise Image for Interventional CT · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06140433 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Philips Clinical & Medical Affairs Global
- Last refreshed: 5 July 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06140433.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing